retatrutide type 2 diabetes trial 2024 🚨Breaking: Retatrutide's first Phase 3 T2D data just dropped. ▸ A1C: −2.0% at 40 weeks ▸ Weight: −36.6 lbs (−16.8%) at 12 mg ▸ No weight loss plateau — curve still descending retatrutide type 2 diabetes phase

Nooms data shows members in its microdosing program can lose up to 11 pounds in 30 days and up to 17 pounds in 60 days, Egler says

Effect and Safety of Adding Metformin to Insulin Therapy in Treating Adolescents with Type 1 Diabetes Mellitus: An Updated Meta-Analysis of 10 Randomized Controlled Trials

Based on published phase 2 clinical trial data, the most commonly reported adverse effects include: Gastrointestinal effects: Nausea, vomiting, diarrhoea, constipation, and reduced appetite are the most frequently reported side effects

For mild to moderate joint discomfort without red flag features, management should be guided by NICE NG226 (Osteoarthritis in over 16s: diagnosis and management) and may include: Exercise and physiotherapy , which are central to NICE-recommended management

The resulting volume loss can compromise facial proportions, leading to psychosocial distress

Potential Interactions Between These Two Medicines No formal interaction studies exist, but pharmacodynamic interactions are a key concern tesamorelin raises blood glucose whilst retatrutide lowers it, making the combined glycaemic effect unpredictable and requiring close clinical monitoring